HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival
Open accessThe DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
Over the past four decades there have been minimal improvements in outcomes for patients with osteosarcoma. New targets and novel therapies are needed to improve outcomes for these patients. We sought to evaluate the prevalence and clinical significance of the newest immune checkpoint, HHLA2, in osteosarcoma. HHLA2 protein expression was evaluated in primary tumor specimens and metastatic disease using an osteosarcoma tumor microarray (TMA) (n = 62). The association of HHLA2 with the presence of tumor infiltrating lymphocytes (TILs) and five-year-event-free-survival were examined. HHLA2 was expressed in 68% of osteosarcoma tumors. HHLA2 was expressed in almost all metastatic disease specimens and was more prevalent than in primary specimens without known metastases (93% vs 53%, p = 0.02). TILs were present in 75% of all osteosarcoma specimens. Patients whose tumors were ≥25% or ≥50% HHLA2 positive had significantly worse five-year event-free-survival (33% vs 64%, p = 0.03 and 14% vs 59%, p = 0.02). Overall, we have shown that HHLA2 is expressed in the majority of osteosarcoma tumors and its expression is associated with metastatic disease and poorer survival. Along with previously reported findings that HHLA2 is a T cell co-inhibitor, these results suggest that HHLA2 may be a novel immunosuppressive mechanism within the osteosarcoma tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Another inhibitory molecule HHLA2, a newly defined B7 family member, widely expressed in osteosarcoma, which is associated with metastases and worse survival [100].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Dissemination and growth of cancer cells in metastatic sites
Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc865 · Cited by 3,911
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · Cancer · doi:10.1002/cncr.24121 · Cited by 2,199
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems
Takayanagi, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2062 · Cited by 1,878
Translational biology of osteosarcoma
Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Ohaegbulam, K. C., Assal, A., Lazar-Molnar, E., Yao, Y., & Zang, X. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.009 · Cited by 843
Self-citationvan Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
Perry, J. A., Kiezun, A., Tonzi, P., Van Allen, E. M., Carter, S. L., Baca, S. C., Cowley, G. S., Bhatt, A. S., Rheinbay, E., Pedamallu, C. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419260111 · Cited by 481
Research works printed but not linked: 1
- Shen J. K. et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res 2, 690– 698, doi: 10.1158/2326-6066.CIR-13-0224 (2014). 24866169 PMC4082476 · DOI · Paper page
Cited by
Advancing therapy for osteosarcoma
Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876
Self-citationAdvances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“Another inhibitory molecule HHLA2, a newly defined B7 family member, widely expressed in osteosarcoma, which is associated with metastases and worse survival [100].”
BackgroundNew B7 Family Checkpoints in Human Cancers
Ni, L., & Dong, C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0761 · Cited by 244
“B7-H7 is expressed in the majority of osteosarcoma tumors and its expression is associated with metastatic disease and poorer survival, suggesting that B7-H7 may be a novel immunosuppressive mechanism within the osteosarcoma tumor microenvironment (103).”
BackgroundThe third group of the B7‐CD 28 immune checkpoint family: HHLA 2, TMIGD 2, B7x, and B7‐H3
Janakiram, M., Shah, U. A., Liu, W., Zhao, A., Schoenberg, M. P., & Zang, X. (2017) · Immunological Reviews · doi:10.1111/imr.12521 · Cited by 225
Self-citationJing, C., Fu, Y., Yi, Y., Zhang, M., Zheng, S.-S., Huang, J., Gan, W., Xu, X., Lin, J., Zhang, J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0554-8 · Cited by 128
Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential
Yang, W., Tang, F., Tu, C., Hornicek, F. J., Duan, Z., & Min, L. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215887 · Cited by 114
Zhou, Q.-H., Li, K.-W., Chen, X., He, H.-X., Peng, S.-M., Peng, S.-R., Wang, Q., Li, Z.-A., Tao, Y.-R., Cai, W.-L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000157 · Cited by 97
Cheng, H., Borczuk, A., Janakiram, M., Ren, X., Lin, J., Assal, A., Halmos, B., Perez-Soler, R., & Zang, X. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2924 · Cited by 90
“The B7x and HHLA2 antibodies have been validated by previously published studies (25, 26, 28, 29).”
BackgroundSelf-citationKIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target
Yao, W., Ren, X., Galbo, P. M., Moerdler, S., Wang, H., Sica, R. A., Etemad-Gilbertson, B. A., Shi, L., Zhu, L., Tang, X.-D., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf9792 · Cited by 92
Self-citationDanieau, G., Morice, S., Rédiní, F., Verrecchia, F., & Royer, B. B.-L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153751 · Cited by 93
“HHLA2 expression has been associated with metastatic properties of osteosarcoma cells and poor survival of osteosarcoma patients [168,169].”
BackgroundCao, L., Wang, J., & Wang, Q. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.10.008 · Cited by 80
Chen, L., Zhu, D., Feng, J., Zhou, Y., Wang, Q., Feng, H., Zhang, J., & Jiang, J. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0813-2 · Cited by 79
B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling
Rieder, S. A., Wang, J., White, N. M., Qadri, A. N., Ménard, C., Stephens, G. L., Karnell, J. L., Rudd, C. E., & Kolbeck, R. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0361-7 · Cited by 77
Pulanco, M. C., Madsen, A. T., Tanwar, A., Corrigan, D. T., & Zang, X. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01019-8 · Cited by 75
Self-citationHan, Y., Qiu, W., de Gonzalez, A. K. K., Wei, J., Tu, M., Xi, C., Yang, Y., Peng, Y., Tsai, W., Remotti, H. E., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.007 · Cited by 72
“The prognostic significance of HHLA2 expression in osteosarcoma was found to be correlated with metastasis and worse survival [26].”
BackgroundZhu, Z., & Dong, W. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s160493 · Cited by 65
“Moreover, we found that the high expression of HHLA2 was associated with poor prognostic features in patients with CRC, which is consistent with previous studies of human lung cancer, breast cancer, and osteosarcoma.(20,27,28) It was noted that the CD8-TILs status was not a predictive value in patient prognosis in thi…”
ResultCD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7+ Tumor Cells
Zhuang, X., & Long, E. O. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0733 · Cited by 68
Sun, W., Li, S., Tang, G., Sun, S., Luo, Y. M., Bai, R., Han, L., Jiang, X., Gao, Y., Huang, Z., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4081 · Cited by 54
Immune checkpoint: The novel target for antitumor therapy
Jiang, X., Liu, G., Li, Y., & Pan, Y. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.12.004 · Cited by 54
“Osteosarcoma patients with higher expression of T cell coinhibitory HHLA2 are associated with metastatic disease and poorer survival.(88) Studies have shown that the HHLA2 may play an important role in lung cancer, especially in tumors that are PD-L1-negative or escape PD-1/PD-L1 blockade.”
BackgroundZhang, Z., Liu, J., Zhang, C., Li, F., Li, L., Wang, D., Chand, D., Guan, F., Zang, X., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00280 · Cited by 48
Self-citationStricker, E., Peckham‐Gregory, E. C., & Scheurer, M. E. (2023) · Biomedicines · doi:10.3390/biomedicines11030936 · Cited by 115
Novel immune checkpoint targets: A promising therapy for cancer treatments
Patwekar, M., Sehar, N., Patwekar, F., Medikeri, A., Ali, S., Aldossri, R. M., & Rehman, M. U. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111186 · Cited by 46
Potential Therapeutic Targets of B7 Family in Colorectal Cancer
Wang, C., Feng, H., Cheng, X., Liu, K., Cai, D., & Zhao, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00681 · Cited by 43
“Several studies showed that overexpression of HHLA2 was significantly correlated with poor survival and clinical outcomes in patients with bladder urothelial carcinoma (60), clear cell renal cell carcinoma (61), osteosarcoma (62), and intrahepatic cholangiocarcinoma (63).”
BackgroundLi, Y., Lv, C., Yu, Y., Wu, B., Zhang, Y., Lang, Q., Liang, Z., Zhong, C., Shi, Y., Han, S., et al. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.07.013 · Cited by 39
“HHLA2 expression is more abundant in metastatic tumours than in primary tumours without metastasis and is also higher in metastatic tissue and primary tumours with metastasis than in primary tumours without metastasis in osteosarcoma [62].”
BackgroundHHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer
Li, W., Tang, L., Chang, H., Huo, S., & Li, Y. (2019) · Human Cell · doi:10.1007/s13577-019-00280-2 · Cited by 37
Luo, M., Lin, Y., Liang, R., Li, Y., & Ge, L. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s324336 · Cited by 41
“HHLA2 expression independently correlates with high TIL density in nonsmall cell lung cancer and renal cell carcinoma,(17,49) but not in osteosarcoma.(18) In lung cancer, HHLA2 expression significantly correlates with EGFR mutations, TIL density,”
BackgroundWang, R., Guo, H., Tang, X., Zhang, T., Liu, Y., Zhang, C., Yu, H., & Li, Y. (2021) · Inflammation · doi:10.1007/s10753-021-01547-3 · Cited by 35
“HHLA2 expression has shown relevance to the tumor infiltration by immune cells such as T cells, B cells, dendritic cells, and macrophages [23, 24].”
BackgroundChen, Q., Wang, J., Chen, W., Zhang, Q., Wei, T., Zhou, Y., Xu, X., Bai, X., & Liang, T. (2018) · Cancer Science · doi:10.1111/cas.13914 · Cited by 34
HHLA2 predicts better survival and exhibits inhibited proliferation in epithelial ovarian cancer
Xu, G., Shi, Y., Ling, X., Wang, D., Liu, Y., Lu, H., Peng, Y., & Zhang, B. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01930-y · Cited by 30
“In breast cancer [8], clear cell renal cell carcinoma [15], colorectal cancer [16], and osteosarcoma [17], high HHLA2 expression is associated with invasive tumour behaviour and worse clinical outcomes.”
BackgroundAdvances and challenges in the treatment of osteosarcoma
Wang, X., Zhu, K., Hu, J., & Zhang, C. (2025) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2025.07.001 · Cited by 38
Ding, L., Yu, Q., Yang, S., Yang, W., Liu, T., Xian, J., Tian, T., Li, T., Chen, W., Wang, B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.831101 · Cited by 34
HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma
Qi, Y., Deng, G., Xu, P., Zhang, H., Yuan, F., Geng, R., Jiang, H., Liu, B., & Chen, Q. (2019) · Oncology Reports · doi:10.3892/or.2019.7343 · Cited by 31
“The prognostic significance of HHLA2 expression in osteosarcoma and colorectal carcinoma was identified to be correlated with metastasis and poor survival (46,47).”
CAR T targets and microenvironmental barriers of osteosarcoma
Zhu, J., Simayi, N., Wan, R., & Huang, W. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2021.12.010 · Cited by 33
Shimonosono, M., Arigami, T., Yanagita, S., Matsushita, D., Uchikado, Y., Kijima, Y., Kurahara, H., Kita, Y., Mori, S., Sasaki, K., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25179 · Cited by 28
“In patients with osteosarcoma, high HHLA2 expression was associated with a significantly worse prognosis [16, 17].”
BackgroundLuo, M., Su, Z., Gao, H., Tan, J., Liao, R., Yang, J., & Lin, L. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04682-7 · Cited by 28
“Indeed, osteosarcoma cells are known to express a number of surface proteins that might be of therapeutic relevance, including B7-H3, GD2 and HER2, which can be targeted using antibody–drug conjugates or adoptive cell therapies [31–33].”
BackgroundYing, H., Xu, J., Zhang, X., Liang, T., & Bai, X. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103987 · Cited by 26
Zhong, C., Lang, Q., Yu, J., Wu, S., Xu, F., & Tian, Y. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13413 · Cited by 24
Huang, J., Xu, Y., & Lin, F. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15716 · Cited by 22
Ramaswamy, M., Kim, T. I., Jones, D. C., Ghadially, H., Mahmoud, T. I., Garcia, A., Browne, G. J., Ζήνωνος, Ζ., Puplampu-Dove, Y., Riggs, J. M., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0218 · Cited by 22
“The biological role of B7H7, the ligand for CD28H, is contentious because it is highly expressed on a variety of tumor tissues, and many studies indicate an inhibitory role on T-cell activation (17, 18, 31, 32).”
BackgroundChakraborty, P., Kuo, R. I., Vervelde, L., Dutia, B. M., Kaiser, P., & Smith, J. (2019) · Genes · doi:10.3390/genes10020074 · Cited by 23
Farrag, M. S., Ibrahim, E., Elhadidy, T. A., Akl, M. F., Elsergany, A. R., & Abdelwahab, H. W. (2021) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2021.22.6.1883 · Cited by 20
“But in triple-negative breast cancer (TNBC), overexpressed HHLA2 was linked to lymph node positivity (Janakiram et al., 2015a).”
BackgroundInfluentialHHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
Huang, F., Wu, J.-W., Cheng, X.-Q., Wang, J.-H., Wen, X., Li, J., Zhang, Q., Jiang, H., Ding, Q.-Y., Zhu, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.902167 · Cited by 21
“Paradoxically, high HHLA2 expression in ICC was associated with low TIL infiltration (15), and there was no clear association in sarcomas (17).”
BackgroundCrosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities
Ren, X., Li, Y., Nishimura, C., & Zang, X. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.009 · Cited by 20
Self-citationOsteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights
Zhang, Y., Jiang, S., Lv, J., Feng, W., Yu, Y., & Zhao, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1584450 · Cited by 29
Overexpression of B7H5/CD28H is associated with worse survival in human gastric cancer
Hu, C., Xu, Z., Chen, S., Lv, H., Wang, Y., Wang, X., Mo, S., Shi, C., Wei, S., Hu, L.-Q., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14812 · Cited by 16
Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes
Cocco, C., Morandi, F., & Airoldi, I. (2021) · Cells · doi:10.3390/cells10040927 · Cited by 18
“In particular, infiltration by DC and macrophages was associated with a worse event free survival at five years [117].”
BackgroundWang, J., Yang, K., Yang, X., Jin, T., Tian, Y., Dai, C., & Xu, F. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23723 · Cited by 15
HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma
Liao, X., & Zhang, D. (2022) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqab221 · Cited by 15
Luu, K., Schwarz, H., & Lundqvist, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.682627 · Cited by 14
Chapoval, A. I., Chapoval, S. P., Shcherbakova, N. S., & Щербаков, Д. Н. (2019) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162019050091 · Cited by 13
Long, L., Zhang, L., Yang, Y., Zhou, Y., & Chen, H. (2022) · Immunotherapy · doi:10.2217/imt-2021-0093 · Cited by 13
Comprehensive molecular profiling of the B7 family in gastrointestinal cancer
Zhao, Q., Hu, F., Xiao, Z., Li, M., Wu, X., Zhao, Y., Wu, Y., Yin, J., Lin, L., Zhang, H., et al. (2018) · Cell Proliferation · doi:10.1111/cpr.12468 · Cited by 11
Methylome-wide association study of early life stressors and adult mental health
Howard, D. M., Pain, O., Arathimos, R., Barbu, M. C., Amador, C., Walker, R. M., Jermy, B. S., Adams, M. J., Deary, I. J., Porteous, D. J., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab274 · Cited by 15
B7-H7: A potential target for cancer immunotherapy
Su, Q., Du, J., Xiong, X., Xie, X., & Wang, L. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110403 · Cited by 11
Ahangar, N. K., Khalaj‐Kondori, M., Alizadeh, N., Mokhtarzadeh, A., Baghbanzadeh, A., Shadbad, M. A., Dolatkhah, K., & Baradaran, B. (2022) · Gene · doi:10.1016/j.gene.2022.147086 · Cited by 10
Zhang, L., Jiang, H., & Ma, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548527 · Cited by 16
Sankin, A. I., Narasimhulu, D. M., John, P., Gartrell, B. A., Schoenberg, M., & Zang, X. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.04.007 · Cited by 10
“[83] Koirala P, Roth ME, Gill J, Chinai JM, Ewart MR, Piperdi S, et al.”
Self-citationAssociation of high PDPN expression with pulmonary metastasis of osteosarcoma and patient prognosis
Wang, X., Li, W., Bi, J., Wang, J., Ni, L., Shi, Q., & Meng, Q. (2019) · Oncology Letters · doi:10.3892/ol.2019.11053 · Cited by 11
“PM is the most reliable prognostic indicator for patients with resectable osteosarcoma, followed by Enneking stage, surgical complications, jumping lesions and local recurrence (17-19).”
BackgroundHigh expression of HHLA2 predicts poor prognosis in medullary thyroid carcinoma
Niu, Y., Wang, W., Jiang, X., Zhang, J., Huang, Y., Jiang, Y., & Jiang, Y. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac040 · Cited by 10
Wu, F., Shen, J., Zhao, Z., Chen, Y., Ren, B., Li, M., Yin, R. H., Zhang, Y., & Yu, S. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218219 · Cited by 12
Yu, B., Geng, C., Wu, Z., Zhang, Z., Zhang, A., Yang, Z., Huang, J., Xiong, Y., Yang, H., & Chen, Z. (2024) · Scientific Reports · doi:10.1038/s41598-023-49770-2 · Cited by 11
“In osteosarcoma, HHLA2 is upregulated in metastasis tumor samples and associated with worse clinical outcomes 69 .”
BackgroundThe clinical significance of HERV-H LTR –associating 2 expression in cervical adenocarcinoma
Byun, J. M., Cho, H. J., Park, H. Y., Lee, D. S., Choi, I. H., Kim, Y. N., Jeong, C. H., Kim, D. H., Im, D. H., Min, B. J., et al. (2021) · Medicine · doi:10.1097/md.0000000000023691 · Cited by 9
“The observed coexpression of HHLA2 and PD-L1 was similar to the pattern reported in osteosarcoma.([17]) However, unlike osteosarcoma, HHLA2 and PD-L1 expression in cervical AC is associated with an improved prognosis.”
BackgroundResultLi, G., Lei, J., Xu, D., Yu, W., Bai, J., & Wu, G. (2023) · Scientific Reports · doi:10.1038/s41598-023-33009-1 · Cited by 11
B7-H7 is a prognostic biomarker in epithelial ovarian cancer
Fu, Y., Ding, Y., Liu, J., Zheng, X. W., Wei, W., Ying, Y., Wu, C., Jiang, J., & Ju, J. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-697 · Cited by 8
“This finding was consistent with previous studies focusing on B7H7 in a variety of other cancers (20,37-42).”
ResultFeng, D., Tuo, Z., Wang, J., Ye, L., Li, D., Wu, R., Wei, W., Yang, Y., & Zhang, C. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23495 · Cited by 8
“Interestingly, previous research found that elevated HHLA2 expression in lung, breast, and osteosarcoma was related with worse prognostic characteristics [114 – 116], offering yet another reason for cluster 1 ’ s poor prognosis.”
BackgroundZhou, S., Wang, Z., Zhao, D., Fu, Y., Zhang, S., Wang, Z., & Zou, X. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03409-2 · Cited by 6
“As a newly discovered member of the B7 family, HHLA2 is absent in most normal tissues, but is over-expressed in some malignant tumors [24].”
BackgroundImmune checkpoints in immune response to glioma: two sides of the same coin
Musatova, O. E., Kumar, V. S., Vinogradov, K., & Rubtsov, Y. P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639521 · Cited by 11
“For example, HHLA2 was found to be highly expressed in osteosarcoma and colorectal carcinomas and positively correlated with metastasis and a poor prognosis (65, 66).”
Fu, Y., Zheng, P., Zheng, X., Chen, L., Kong, C., Liu, W., Li, S., & Jiang, J. (2023) · Cellular Immunology · doi:10.1016/j.cellimm.2023.104730 · Cited by 7
“HHLA2 has been proven to be a potential target for cancer immunotherapy, which is highly expressed in several human cancers [23,24,25] .”
BackgroundGong, L., Sun, X., & Jia, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-45566-6 · Cited by 5
CD28 family of receptors inter-connect in the regulation of T-cells
Krueger, J., Jules, F., Rieder, S. A., & Rudd, C. E. (2017) · Receptors & Clinical Investigation · doi:10.14800/rci.1581 · Cited by 6
“Aberrant expression of B7H7 has been observed in various cancer types including lung [42] osteosarcoma [43] and pancreatic cancers [44].”
BackgroundZhang, Y., Zhao, Z., Fu, W., & Ding, S. (2023) · Helicobacter · doi:10.1111/hel.12999 · Cited by 4
Prognostic Value of HHLA2 in Patients with Solid Tumors: A Meta-Analysis
Kula, A., Dawidowicz, M., Mielcarska, S., Świętochowska, E., & Waniczek, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094760 · Cited by 5
“…survival rates in patients with various types of cancer, such as prostate cancer [12], hepatocellular carcinoma [13], lung adenocarcinoma [10], gastric cancer [14], bladder urothelial carcinoma [15], cholangiocarcinoma [16], colorectal carcinoma [17], osteosarcoma [18], and breast cancer [19].”
BackgroundSorteberg, A. L., Ek, L., Lilienthal, I., & Herold, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_236-1 · Cited by 2
Ogoshi, K., Iwata, K., Kunisaki, C., Takenoshita, S., & Isono, K. (2024) · Annals of Cancer Research and Therapy · doi:10.4993/acrt.32.17 · Cited by 4
Distinct Roles of HHLA2 and PD-L1 in the Immune Cell and Prognosis of Hepatocellular Carcinoma
Wang, C., Chen, S.-L., Yang, X., Wu, T., Liu, L., & Yun, J. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s513033 · Cited by 4
“32 Additionally, a negative correlation between HHLA2 over-expression and cytotoxic T cells was found in Intrahepatic cholangiocarcinoma.”
Gawesh, Z. M. A., Ibrahim, E., Elkalla, H., Awad, A. A. E.-H., & Mohamed, M. (2023) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2023.24.12.4309 · Cited by 2
“…agreement with preceding research in stomach cancer (Wei et al., 2019), lung adenocarcinoma (Chen et al., 2020; Farrag et al., 2021), osteosarcoma (Koirala et al., 2016), bladder cancer (Lin et al., 2019), intrahepatic cholangiocarcinoma (Jing et al., 2019), clear cell RCC (Chen et al., 2019;…”
ResultNext generation immune checkpoints
Perez, N. M., Moziak, K., & Martin, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.90009-2 · Cited by 1
Liu, F., Qin, Y., Luo, W., Ruan, X., Lu, L., Feng, B., & Yu, J. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1530334 · Cited by 1
“It has been discovered that several solid tumors have high expressions of HHLA2, including breast cancer (Liu et al., 2017), osteosarcoma (Koirala et al., 2016), colon cancer (Zhu and Dong, 2018), clear cell carcinoma of the kidney (Chen et al., 2019), and bladder cancer (Lin et al., 2019), and so…”
Sorteberg, A. L., Ek, L., Lilienthal, I., & Herold, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_236 · Cited by 1
Cell–Cell Interactome-Based Pathogenesis and Therapies for Osteosarcoma
Neelam, S., Hakeem, A., Yang, Y., & Yang, S. (2026) · Cells · doi:10.3390/cells15060570 · Cited by 1
“In parallel, NK cells contribute to early immune control of disseminated tumor cells, particularly when their activity is augmented through adoptive transfer or antibody-dependent mechanisms [83].”
InfluentialWang, C., Chen, S.-L., Yang, X., Wu, T., Liu, L., & Yun, J. (2022) · Research Square · doi:10.21203/rs.3.rs-2319886/v1 · Cited by 1
Immuno-oncologic Approach to Musculoskeletal Tumors
Ibe, I. K., Sahlstrom, A., Nguyen, M. N., Lindskog, D. M., Friedlaender, G. E., & Lee, F. Y. (2018) · Techniques in Orthopaedics · doi:10.1097/bto.0000000000000305
Zhang, Y., Xu, M., Yin, J., Li, C., Ye, Z., & Shang, J. (2020) · doi:10.21203/rs.3.rs-20244/v1
“The role of HHLA2 in ccRCC requires further investigation to explore its potential value as a novel immunotherapeutic target(39).”
BackgroundNiu, Y., Wang, W., Jiang, X., Zhang, J., Huang, Y., Yan, S. W., & Jiang, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-192469/v1
“Subsequently, other researchers also reported a high upregulation of HHLA2 in various malignant tumor tissues, such as colorectal cancer [20], gastric cancer [21], lung cancer [7, 25, 26], osteosarcoma [27], bladder cancer [28], liver cancer [29] and clear cell renal cell carcinoma [30].”
BackgroundBolandi, N., Ansari, M. H. K., Rasmi, Y., & Baradaran, B. (2022) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2023.055 · Cited by 1
“Recent data indicated that B7-H7 is overexpressed in tumor cells in different kinds of cancers, such as renal cell carcinoma (10), bladder cancer (11), colorectal cancer (12), lung cancer (13, 14), osteosarcoma (15), breast cancer (6), and GC (16).”
BackgroundRamaswamy, M., Kim, T. I., Jones, D. C., Ghadially, H., Mahmoud, T. I., Garcia, A. J., Browne, G. J., Ζήνωνος, Ζ., Puplampu-Dove, Y., Riggs, J. M., et al. (2023) · doi:10.1158/2326-6066.c.6550767
WITHDRAWN: Next generation immune checkpoints
Perez, N. M., Moziak, K., & Martin, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00009-6
Wen, J., Wan, L., Chen, W., & Dong, X. (2024) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-024-04781-1
Wen, J., Wan, L., Chen, W., & Dong, X. (2024) · Figshare · doi:10.6084/m9.figshare.26734449
Zhou, S., Wang, Z., Zhao, D., Fu, Y., Zhang, S., Wang, Z., & Zou, X. (2024) · Figshare · doi:10.6084/m9.figshare.25854623
Luo, M., Su, Z., Gao, H., Tan, J., Liao, R., Yang, J., & Lin, L. (2023) · Figshare · doi:10.6084/m9.figshare.24797864
Wen, J., Wan, L., Chen, W., & Dong, X. (2024) · Figshare · doi:10.6084/m9.figshare.26734452
Luo, M., Su, Z., Gao, H., Tan, J., Liao, R., Yang, J., & Lin, L. (2024) · Figshare · doi:10.6084/m9.figshare.26652612
Wen, J., Wan, L., Chen, W., & Dong, X. (2024) · Figshare · doi:10.6084/m9.figshare.26734455
Luo, M., Su, Z., Gao, H., Tan, J., Liao, R., Yang, J., & Lin, L. (2024) · Figshare · doi:10.6084/m9.figshare.24798094
Wen, J., Wan, L., Chen, W., & Dong, X. (2024) · Figshare · doi:10.6084/m9.figshare.26734446
Rôle de la voie de signalisation Hippo dans le développement des ostéosarcomes
Morice, S. (2019) · theses.fr (ABES) · doi:10.70675/32829b80z5982z4f52z949bz98b3ed38b7c0
Conséquences de l'engagement de CD28H sur les cellules "Natural Killer" humaines
Duplouye, P. (2020) · theses.fr (ABES) · doi:10.70675/ebac822ez44aaz4a68zbd6az7ecfb4157aa2
Yu, Y., You, J., Wang, X., Xue, H., Chen, H., & Li, W. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1898263
“Functioning as part of a receptor complex, KCTD12 primarily interacts with the gamma-aminobutyric acid-B (GABA-B) receptor, thereby mediating K + current desensitisation upon GABA-B receptor activation (16, 24).”
Metadata
- Authors
- Koirala, P., Roth, M. E., Gill, J., Chinai, J. M., Ewart, M. R., Piperdi, S., Geller, D. S., Hoang, B. H., Fatakhova, Y. V., Ghorpade, M., Zang, X., & Gorlick, R.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Zang, Xingxing
- Gorlick, Richard
- Venue
- Scientific Reports
- Published
- 2016-08-17
- Volume
- 6
- Issue
- 1
- Pages
- 31154-31154
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4987662
- OpenAlex
- W2517687042
- Cited by
- 100
- References
- 34
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 16 · 2023: 14 · 2022: 11 · 2021: 15 · 2020: 9 · 2019: 12 · 2018: 7 · 2017: 4 · 2016: 1
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense (PC131008)
- Swim Across America
- National Institutes of Health (5k12ca132783-12, 1s10od019961-01)
- National Cancer Institute (K12-CA132783, R01CA175495)
- National Institute of General Medical Sciences (T32GM007288)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK100525)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Keywords
- HHLA2, B7 family, osteosarcoma, immune checkpoint, metastasis, tumor-infiltrating lymphocytes, event-free survival, tumor microenvironment, immunosuppression, T cell co-inhibition
- MeSH terms
- Adolescent, Adult, Bone Neoplasms, Child, Female, Humans, Immunoglobulins, Male, Prognosis, Osteosarcoma, Biomarkers, Tumor, Lymphocytes, Tumor-Infiltrating, Disease-Free Survival, Protein Array Analysis, Kaplan-Meier Estimate, Young Adult, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.